Worth reading
56In focus
Scored from 3 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
49
当社出資比率（％）Wording
Definitive
How definitive the wording is.This transaction
Quaero社を引受先とするNPSへの増資Counterparty嘉兴凯实生物科技股份有限公司（英語名 Quaero Life Science Co., Ltd）（Quaero社）
Disclosing companyPrecision System Science Co.,Ltd.
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.The percentage before the change is not stated in this document.
Execution Date / Effective Date2025年9月30日（本日付、完了）
Impact on Business Performance
すでに当連結会計年度の業績予想に含まれており、業績予想の変更はありません
Procedures and assumptions
Management structure after acquisitionNPSは持分法適用関連会社となった。商号、代表者、従業員の処遇はNot disclosed
| Item | Details |
|---|---|
| Transaction name | Quaero社を引受先とするNPSへの増資 |
| Counterparty name | 嘉兴凯实生物科技股份有限公司（英語名 Quaero Life Science Co., Ltd）（Quaero社） |
| Name of the Subject Company | エヌピーエス株式会社（NPS） |
| Voting rights ownership percentage | After 49% (before not disclosed) |
| Impact on Business Performance | すでに当連結会計年度の業績予想に含まれており、業績予想の変更はありません |
| Execution Date / Effective Date | 2025年9月30日（本日付、完了） |
| Management structure after acquisition | NPSは持分法適用関連会社となった。商号、代表者、従業員の処遇はNot disclosed |
Items this document does not state (25)
Business Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Date of board resolutionContract DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to Execution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.会社は、本件が2025年6月27日に公表した投資契約に基づくものであることを説明している。取引の事業上の目的・理由は記載していない。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.